Related Experiment Video
Updated: Sep 22, 2025
07:44
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
380
Pediatric CNS cancer genomics and immunogenomics
Katherine E Miller1, Elaine R Mardis1
1The Rasmussen Institute for Genomic Medicine at Nationwide Children's Hospital, USA; The Ohio State University College of Medicine, Department of Pediatrics, USA.
Current Opinion in Genetics & Development
|May 26, 2022
Summary
Genomic studies in pediatric cancers highlight the need for multi-platform DNA and RNA analysis. Multiplex characterization in pediatric central nervous system (CNS) malignancies shows precision therapeutics offer clinical benefits.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Large-scale genomic studies in pediatric cancers emphasize multi-platform DNA and RNA characterization.
- This comprehensive molecular profiling is crucial for identifying actionable variants, diagnostic/prognostic markers, and germline susceptibility.
- Implementation of precision medicine in pediatric oncology lags behind adult settings due to cancer rarity.
Purpose of the Study:
- To review large-cohort studies using multiplex clinical characterization in pediatric cancers, particularly central nervous system (CNS) malignancies.
- To assess the clinical benefit of molecularly guided precision therapeutics in this population.
- To identify key components for advancing precision therapeutics in pediatric CNS cancers.
Main Methods:
- Survey of large-cohort studies involving multiplex clinical characterization.
- Inclusion of pediatric patients with central nervous system (CNS) malignancies.
- Analysis of reported outcomes for molecularly guided precision therapeutics.
Main Results:
- Multiplex characterization provides a comprehensive molecular landscape of pediatric cancers.
- Molecularly guided precision therapeutics demonstrated clinical benefit in pediatric CNS malignancy patients.
- These findings support the integration of precision therapeutics into pediatric CNS cancer care.
Conclusions:
- Multi-platform genomic characterization is essential for pediatric cancer precision medicine.
- Precision therapeutics show promise and clinical benefit for pediatric CNS malignancies.
- Further implementation of these strategies is needed to advance pediatric cancer care.
More Related Videos
Related Concept Videos
01:33Cancer-Critical Genes I: Proto-oncogenes
9.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
02:21Cancers Originate from Somatic Mutations in a Single Cell
13.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.1K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K